| 20438-8 |
Glucose^1H post dose glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1 hour post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL.ROUTINE |
|
20438-8 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 1h p Glc SerPl-mCnc |
|
|
|
Y |
|
1 hour; 1.0Hr; 1h p Glc; 60 min; 60 minutes; 60M; 60min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Class from "CHAL" to "CHAL.ROUTINE" |
0 |
| 20439-6 |
Glucose^30M post dose glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --30 minutes post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
20439-6 |
|
|
|
|
Both |
|
|
|
0 |
Glucose 30M p Glc SerPl-mCnc |
|
|
|
Y |
|
30M p Glc; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
Changed Order_Obs from 'Observation Only' to 'Both' to fit current order use cases. |
0 |
| 2044-6 |
Carnitine |
MCnc |
Semen |
Pt |
Qn |
|
|
DISCOURAGED |
Carnitine [Mass/volume] in Semen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2044-6 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine Smn-mCnc |
|
|
|
Y |
|
Carnitine.total; Chemistry; Ejaculate; Genitourinary; GU; Level; Mass concentration; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; URO; Urology |
2.42 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20440-4 |
Glucose^1.5H post dose glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --1.5 hours post dose glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
20440-4 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose 1.5h p Glc SerPl-mCnc |
|
|
|
Y |
|
1 1/2 hours; 1 1/2 HR; 1.5h p Glc; 1.5Hr; 90 min; 90 minutes; 90M; 90min; After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p dose; p Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 20441-2 |
Glucose^post 50 g glucose |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glucose [Mass/volume] in Serum or Plasma --post 50 g glucose |
|
MIN |
DefinitionDescription |
|
|
mg/dL |
|
|
|
|
|
|
CHAL |
|
20441-2 |
|
|
|
|
Observation |
|
|
|
0 |
Glucose p 50 g Glc SerPl-mCnc |
|
|
|
Y |
|
After; CHEMISTRY.CHALLENGE TESTING; Endocrine; Endocrinology; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; Level; Mass concentration; p 50 g Glc; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
mg/dL |
|
|
|
0 |
| 20442-0 |
Hepatitis B virus DNA |
NCnc |
Ser |
Pt |
Qn |
Probe.amp.sig |
|
ACTIVE |
Hepatitis B virus DNA [#/volume] (viral load) in Serum by Probe with signal amplification |
|
MIN |
DefinitionDescription |
|
|
10*6 eq/mL |
|
|
|
|
|
|
MICRO |
|
20442-0 |
|
Probe.amp.sig |
|
|
Both |
|
|
|
0 |
HBV DNA # Ser Probe+sig amp |
|
|
|
Y |
|
#; ABS; absolute; absolutes; Amplif; Amplification; Amplified; bDNA; Bdn-A; Branched Chain DNA; Cnt; Count; Count/volume; CT; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; HBV; HC; Hep; Hep B; Hepatis; Hepatit; Hepatology; HepB; HPA; Hybidization Protection Assay; Hybrid Capture; Hybrid Capture nucleic acid hybridization; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Number concentration; Number Concentration (count/vol); Point in time; Probe amp; Probe with ampification; Probe with signal amplification; Probe+sig amp; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Viral load |
2.73 |
1.0m |
|
|
|
|
|
|
|
10*6{viral equivalents}/mL |
|
|
|
0 |
| 20444-6 |
Herpes simplex virus 1+2 DNA |
PrThr |
XXX |
Pt |
Ord |
Probe.amp.tar |
|
ACTIVE |
Herpes simplex virus 1+2 DNA [Presence] in Specimen by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20444-6 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HSV1+2 DNA Spec Ql NAA+probe |
|
|
|
|
|
3 Self-Sustaining Sequence Replication; 3SR SR; Amplif; Amplification; Amplified; Deoxyribonucleic acid; DNA NUCLEIC ACID PROBE; DNA probe; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type 1+2; Herpes simplex virus type I+II; HSV; HSV 1+2; HSV1; HSV1+2; i; ID; II; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; Misc; Miscellaneous; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Ordinal; Other; PCR; Point in time; Polymerase chain reaction; PR; Probe amp; Probe with ampification; Probe with target amplification; QBR; QL; Qual; Qualitative; Random; Screen; SDA; Spec; Strand Displacement Amplification; TMA; To be specified in another part of the message; Transcription mediated amplification; UniversalLabOrders; Unspecified |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20445-3 |
Herpes virus |
Prid |
XXX |
Pt |
Nom |
Organism specific culture |
|
ACTIVE |
Herpes virus identified in Specimen by Organism specific culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20445-3 |
|
Organism specific culture |
|
|
Both |
|
|
|
0 |
HHV Spec Cult |
|
|
|
|
|
C&S; Cult; Cultures; Herpesvirus; HHV; Human herpes virus; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Misc; Miscellaneous; Nominal; Other; Point in time; Random; Spec; To be specified in another part of the message; Unspecified |
2.79 |
1.0m |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 20446-1 |
Herpes simplex virus Ab.IgG |
Imp |
Ser |
Pt |
Nom |
IA |
|
ACTIVE |
Herpes simplex virus IgG Ab [Interpretation] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20446-1 |
|
IA |
|
|
Observation |
|
|
|
0 |
HSV IgG Ser IA-Imp |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; EIA; ELFA; ELISA; Enzyme immunoassay; Herp splx; HSV; IAA; ID; Immune globulin G; Immunoglobulin G; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; MEIA; Microbiology; Nominal; Point in time; Random; Serum; SR; SUDS |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20447-9 |
HIV 1 RNA |
NCnc |
Ser/Plas |
Pt |
Qn |
Probe.amp.tar |
|
ACTIVE |
HIV 1 RNA [#/volume] (viral load) in Serum or Plasma by NAA with probe detection |
|
MIN |
DefinitionDescription |
|
|
copies/mL |
|
|
|
|
|
|
MICRO |
|
20447-9 |
|
Probe.amp.tar |
|
|
Both |
|
|
|
0 |
HIV1 RNA # SerPl NAA+probe |
|
|
|
Y |
|
#; 3 Self-Sustaining Sequence Replication; 3SR SR; ABS; absolute; absolutes; AIDS; Amplif; Amplification; Amplified; Cnt; Count; Count/volume; CT; DNA NUCLEIC ACID PROBE; DNA probe; HIV type 1; HIV type I; HIV1; Human immunodeficiency virus; i; ID; Infectious Disease; InfectiousDisease; LAT; LCR; Ligase chain reaction; Ligation-activated transcription; Microbiology; NAA+probe; NAAT; NASBA; Nucleic acid sequence based analysis; Number concentration; Number Concentration (count/vol); PCR; Pl; Plasma; Plsm; Point in time; Polymerase chain reaction; Probe amp; Probe with ampification; Probe with target amplification; QBR; QNT; Quan; Quant; Quantitative; Random; Ribonucleic acid; SDA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Strand Displacement Amplification; TMA; Transcription mediated amplification; UniversalLabOrders; Viral load |
2.73 |
1.0m |
|
|
|
|
|
|
|
{copies}/mL |
|
|
|
168 |
| 20448-7 |
Insulin |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Units/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
uIU/mL |
|
|
|
|
|
|
CHEM |
|
20448-7 |
|
|
|
|
Both |
|
|
|
0 |
Insulin SerPl-aCnc |
|
|
|
Y |
|
Arbitrary concentration; Chemistry; Endocrine; Endocrinology; HUM; Humulin; IH7; Insul; Lente; NPH; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
u[IU]/mL |
|
|
|
220 |
| 20449-5 |
Borrelia burgdorferi Ab |
PrThr |
Ser |
Pt |
Ord |
IA |
|
ACTIVE |
Borrelia burgdorferi Ab [Presence] in Serum by Immunoassay |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20449-5 |
|
IA |
|
|
Both |
|
|
|
0 |
B burgdor Ab Ser Ql IA |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B burg; B burgdor; B burgdorferi; Bb; Burgdorf; EIA; ELFA; ELISA; Enzyme immunoassay; IAA; ID; Infectious Disease; InfectiousDisease; Lyme; Lyme disease; Lymes; MEIA; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; SUDS; UniversalLabOrders |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016.; The EIA method, which was always intended to cover more than just enzyme-linked immunoassay and whose display name for the long common name has always been Immunoassay, was renamed IA in order to eliminate ambiguity about whether the method has a broader meaning than just enzyme-linked immunoassay. Likewise, EIA.rapid was renamed IA.rapid. These changes were approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 2045-3 |
Carnitine |
PrThr |
Ser/Plas |
Pt |
Ord |
|
|
ACTIVE |
Carnitine [Presence] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2045-3 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine SerPl Ql |
|
|
|
|
|
Carnitine.total; Chemistry; Ordinal; Pl; Plasma; Plsm; Point in time; PR; QL; Qual; Qualitative; Random; Screen; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20450-3 |
Alpha-1-Fetoprotein |
MoM |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Alpha-1-Fetoprotein [Multiple of the median] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
M.o.M |
|
|
|
|
|
|
CHEM |
|
20450-3 |
|
|
|
|
Observation |
|
|
|
0 |
AFP MoM SerPl |
|
|
|
Y |
|
A1; AFP; Alfa; Alpha fetoprotein; Alphafetoprotein; Chemistry; Feto; i; MoM; Multiple of the median; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tumor marker |
2.73 |
1.0m |
|
|
|
|
|
|
|
{M.o.M} |
|
|
|
0 |
| 20451-1 |
Thyroxine |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Thyroxine (T4) [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
20451-1 |
|
|
|
|
Both |
|
|
|
0 |
T4 Bld Ql |
|
|
|
|
|
Blood; Chemistry; Endocrine; Endocrinology; Levothyroxine; Levo-thyroxine; L-thyroxine; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; T4; T-4; thyroid hormone; Thyrox; Thyroxin; Thyrx; Total T4; TT4; WB; Whole blood |
2.56 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20452-9 |
Thyrotropin |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Thyrotropin [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
20452-9 |
|
|
|
|
Both |
|
|
|
0 |
TSH Bld Ql |
|
|
|
|
|
Blood; Chemistry; Endocrine; Endocrinology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Thyroid stimulating hormone; Thyrotropic hormone; TSH; WB; Whole blood |
2.56 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20453-7 |
Epithelial cells |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Epithelial cells [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
20453-7 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Epi Cells UrnS Ql Micro |
|
|
|
|
|
Cell; Cellularity; Epi; Epi Cells; Epith; Epithelia; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20454-5 |
Protein |
PrThr |
Urine |
Pt |
Ord |
Test strip |
|
ACTIVE |
Protein [Presence] in Urine by Test strip |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
20454-5 |
|
Test strip |
|
|
Observation |
|
|
|
0 |
Prot Ur Ql Strip |
|
|
|
|
|
Dip stick; Dipstick; Kidney; Nephrology; Ordinal; Point in time; PR; Prot; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urn |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20455-2 |
Leukocytes |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Leukocytes [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
20455-2 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
WBC UrnS Ql Micro |
|
|
|
|
|
Kidney; Leuc; Leuk; Leukocyte; Lkcs; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS; WBC; WBCs; White blood cell; White blood cells |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20456-0 |
Fungi.yeastlike |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Fungi.yeastlike [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
20456-0 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Yeast Like Fungi UrnS Ql Micro |
|
|
|
|
|
ID; Infectious Disease; InfectiousDisease; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS; Yeast Like Fungi |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20457-8 |
Fungi.filamentous |
PrThr |
Urine sed |
Pt |
Ord |
Microscopy.light |
|
ACTIVE |
Fungi.filamentous [Presence] in Urine sediment by Light microscopy |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
UA |
|
20457-8 |
|
Microscopy.light |
|
|
Observation |
|
|
|
0 |
Filament Fungi UrnS Ql Micro |
|
|
|
|
|
Filament; Filament Fungi; Fungal hyphae; ID; Infectious Disease; InfectiousDisease; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Renal; Screen; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 20458-6 |
Rubella virus Ab.IgG |
Imp |
Ser |
Pt |
Nom |
|
|
ACTIVE |
Rubella virus IgG Ab [Interpretation] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20458-6 |
|
|
|
|
Observation |
|
|
|
0 |
RUBV IgG Ser-Imp |
|
|
|
|
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Congenital rubella syndrome; German measles; ID; Immune globulin G; Immunoglobulin G; Impression; Impression/interpretation of study; Impressions; Infectious Disease; InfectiousDisease; Interp; Interpretation; Microbiology; Nominal; Point in time; Random; RUBV; Serum; SR |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 20459-4 |
Streptococcus agalactiae Ag |
PrThr |
XXX |
Pt |
Ord |
LA |
|
ACTIVE |
Streptococcus agalactiae Ag [Presence] in Specimen by Latex agglutination |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
20459-4 |
|
LA |
|
|
Both |
|
|
|
0 |
Gp B Strep Ag Spec Ql LA |
|
|
|
|
|
Antigen; Antigens; GBS; Gp B Strep; Group B; Group B Strep; ID; Infectious Disease; InfectiousDisease; LAT; Latex agglutination; Microbiology; Misc; Miscellaneous; Ordinal; Other; Point in time; PR; QL; Qual; Qualitative; Random; S agalactiae; Screen; Spec; Steptococcus Group B; Strep; Strep B; Strep group B; Strept; Streptococci group B; To be specified in another part of the message; Unspecified |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 2046-1 |
Carnitine |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
DISCOURAGED |
Carnitine [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
CHEM |
|
2046-1 |
|
|
|
|
Both |
|
|
|
0 |
Carnitine SerPl-mCnc |
|
|
|
Y |
|
Carnitine.total; Chemistry; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
1 |
|
|
|
AssociatedObservations |
EXTERNAL_COPYRIGHT_LINK |
HL7_ATTACHMENT_STRUCTURE |
CONSUMER_NAME |
EXAMPLE_UCUM_UNITS |
STATUS_REASON |
STATUS_TEXT |
CHANGE_REASON_PUBLIC |
COMMON_TEST_RANK |
COMMON_ORDER_RANK |
| 20460-2 |
Cefuroxime.oral |
Susc |
Isolate |
Pt |
OrdQn |
MIC |
|
ACTIVE |
Cefuroxime Oral [Susceptibility] by Minimum inhibitory concentration (MIC) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
20460-2 |
|
MIC |
|
|
Observation |
|
|
|
0 |
Cefuroxime Oral Islt MIC |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; c308; C33; Ceftin; Cefuroxime Axetil; Cefuroxime Oral; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Minimum inhibitory concentration; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Zinacef |
2.73 |
1.0m |
|
|
|
|
|
|
|
|
|
|
|
0 |
